Fluid suppression in amide proton transfer‐weighted (<scp>APTw) CEST</scp> imaging: New theoretical insights and clinical benefits
Jan‐Rüdiger Schüre(Friedrich-Alexander-Universität Erlangen-Nürnberg), Moritz Zaiß(Friedrich-Alexander-Universität Erlangen-Nürnberg), Patrick Liebig(Siemens Healthineers (Germany)), Laura Mancini(University College London), Julie Poujol, Maria Sedykh(Friedrich-Alexander-Universität Erlangen-Nürnberg), Nándor Pintér(Dent Neurologic Institute), Nathalie Boddaert(St Nicholas Hospital), Laszlo Mechtler(American Academy of Neurology), Sotirios Bisdas(Queen Mary University of London), Ramin Jafari(Philips (United States)), Manuel Schmidt(Friedrich-Alexander-Universität Erlangen-Nürnberg), Lucia Nichelli(Sorbonne Université), Stefano Casagranda(Olea Medical (France)), Arnd Doerfler(Universitätsklinikum Erlangen), Christos Papageorgakis(Olea Medical (France)), Volodia Dangouloff‐Ros(Hôpital Necker-Enfants Malades)
Cited by 18
Related Papers
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
|The Lancet Oncology|2017|1.1k
Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes
|Acta Neuropathologica|2015|676
Pros and cons of ultra-high-field MRI/MRS for human application
|Progress in Nuclear Magnetic Resonance Spectroscopy|2018|542